author_facet Chen, Hongda
Li, Ni
Shi, Jufang
Ren, Jiansong
Liu, Chengcheng
Zhang, Yueming
Jiang, Zheng
Zhang, Zhihui
Dai, Min
Chen, Hongda
Li, Ni
Shi, Jufang
Ren, Jiansong
Liu, Chengcheng
Zhang, Yueming
Jiang, Zheng
Zhang, Zhihui
Dai, Min
author Chen, Hongda
Li, Ni
Shi, Jufang
Ren, Jiansong
Liu, Chengcheng
Zhang, Yueming
Jiang, Zheng
Zhang, Zhihui
Dai, Min
spellingShingle Chen, Hongda
Li, Ni
Shi, Jufang
Ren, Jiansong
Liu, Chengcheng
Zhang, Yueming
Jiang, Zheng
Zhang, Zhihui
Dai, Min
BMJ Open
Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
General Medicine
author_sort chen, hongda
spelling Chen, Hongda Li, Ni Shi, Jufang Ren, Jiansong Liu, Chengcheng Zhang, Yueming Jiang, Zheng Zhang, Zhihui Dai, Min 2044-6055 2044-6055 BMJ General Medicine http://dx.doi.org/10.1136/bmjopen-2018-025935 <jats:sec><jats:title>Introduction</jats:title><jats:p>Screening for colorectal cancer (CRC) is effective in reducing the disease burden. However, high-level evidence from randomised controlled trials on the effectiveness of CRC screening modalities is still lacking. We will conduct a large-scale multicentre randomised controlled trial in China to evaluate the effectiveness and cost-effectiveness of different CRC screening strategies.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>20 000 eligible participants aged 50–74 years are enrolled in five provinces in China. After providing signed informed consent, the participants will be randomised into one of the three screening groups: (1) one-time colonoscopy (n=4000), (2) annual faecal immunochemical test (FIT) (n=8000) and (3) annual risk-adapted screening strategy (n=8000). The risk-adapted screening strategy will use an established CRC risk scoring system, the Asia-Pacific Colorectal Screening score. Participants at high risk of CRC will be referred for colonoscopy, while participants at low risk will be referred for an FIT. Information on clinical reports, epidemiological risk factors and health economic factors will be collected and stored in a web-based data management system. We will further request the participants to donate blood, faecal and saliva samples before conducting the colonoscopy. The primary outcome will be the detection rate of advanced colorectal neoplasia and the secondary outcomes will include the rates of CRC-related mortality, incidence of CRC, participation and complications. The study will last for at least 4 years and the cohort will be followed for 10 years to adequately answer the scientific questions.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>This study was approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences and Peking Union Medical College (18-013/1615). The results of the study will be submitted for publication in peer-reviewed journals and will be discussed by policy and decision makers.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p>ChiCTR1800015506.</jats:p></jats:sec> Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial BMJ Open
doi_str_mv 10.1136/bmjopen-2018-025935
facet_avail Online
Free
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEzNi9ibWpvcGVuLTIwMTgtMDI1OTM1
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEzNi9ibWpvcGVuLTIwMTgtMDI1OTM1
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint BMJ, 2019
imprint_str_mv BMJ, 2019
issn 2044-6055
issn_str_mv 2044-6055
language English
mega_collection BMJ (CrossRef)
match_str chen2019comparativeevaluationofnovelscreeningstrategiesforcolorectalcancerscreeninginchinatargetcastudyprotocolforamulticentrerandomisedcontrolledtrial
publishDateSort 2019
publisher BMJ
recordtype ai
record_format ai
series BMJ Open
source_id 49
title Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_unstemmed Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_full Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_fullStr Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_full_unstemmed Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_short Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_sort comparative evaluation of novel screening strategies for colorectal cancer screening in china (target-c): a study protocol for a multicentre randomised controlled trial
topic General Medicine
url http://dx.doi.org/10.1136/bmjopen-2018-025935
publishDate 2019
physical e025935
description <jats:sec><jats:title>Introduction</jats:title><jats:p>Screening for colorectal cancer (CRC) is effective in reducing the disease burden. However, high-level evidence from randomised controlled trials on the effectiveness of CRC screening modalities is still lacking. We will conduct a large-scale multicentre randomised controlled trial in China to evaluate the effectiveness and cost-effectiveness of different CRC screening strategies.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>20 000 eligible participants aged 50–74 years are enrolled in five provinces in China. After providing signed informed consent, the participants will be randomised into one of the three screening groups: (1) one-time colonoscopy (n=4000), (2) annual faecal immunochemical test (FIT) (n=8000) and (3) annual risk-adapted screening strategy (n=8000). The risk-adapted screening strategy will use an established CRC risk scoring system, the Asia-Pacific Colorectal Screening score. Participants at high risk of CRC will be referred for colonoscopy, while participants at low risk will be referred for an FIT. Information on clinical reports, epidemiological risk factors and health economic factors will be collected and stored in a web-based data management system. We will further request the participants to donate blood, faecal and saliva samples before conducting the colonoscopy. The primary outcome will be the detection rate of advanced colorectal neoplasia and the secondary outcomes will include the rates of CRC-related mortality, incidence of CRC, participation and complications. The study will last for at least 4 years and the cohort will be followed for 10 years to adequately answer the scientific questions.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>This study was approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences and Peking Union Medical College (18-013/1615). The results of the study will be submitted for publication in peer-reviewed journals and will be discussed by policy and decision makers.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p>ChiCTR1800015506.</jats:p></jats:sec>
container_issue 4
container_start_page 0
container_title BMJ Open
container_volume 9
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792337272523194386
geogr_code not assigned
last_indexed 2024-03-01T15:13:42.48Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Comparative+evaluation+of+novel+screening+strategies+for+colorectal+cancer+screening+in+China+%28TARGET-C%29%3A+a+study+protocol+for+a+multicentre+randomised+controlled+trial&rft.date=2019-04-01&genre=article&issn=2044-6055&volume=9&issue=4&pages=e025935&jtitle=BMJ+Open&atitle=Comparative+evaluation+of+novel+screening+strategies+for+colorectal+cancer+screening+in+China+%28TARGET-C%29%3A+a+study+protocol+for+a+multicentre+randomised+controlled+trial&aulast=Dai&aufirst=Min&rft_id=info%3Adoi%2F10.1136%2Fbmjopen-2018-025935&rft.language%5B0%5D=eng
SOLR
_version_ 1792337272523194386
author Chen, Hongda, Li, Ni, Shi, Jufang, Ren, Jiansong, Liu, Chengcheng, Zhang, Yueming, Jiang, Zheng, Zhang, Zhihui, Dai, Min
author_facet Chen, Hongda, Li, Ni, Shi, Jufang, Ren, Jiansong, Liu, Chengcheng, Zhang, Yueming, Jiang, Zheng, Zhang, Zhihui, Dai, Min, Chen, Hongda, Li, Ni, Shi, Jufang, Ren, Jiansong, Liu, Chengcheng, Zhang, Yueming, Jiang, Zheng, Zhang, Zhihui, Dai, Min
author_sort chen, hongda
container_issue 4
container_start_page 0
container_title BMJ Open
container_volume 9
description <jats:sec><jats:title>Introduction</jats:title><jats:p>Screening for colorectal cancer (CRC) is effective in reducing the disease burden. However, high-level evidence from randomised controlled trials on the effectiveness of CRC screening modalities is still lacking. We will conduct a large-scale multicentre randomised controlled trial in China to evaluate the effectiveness and cost-effectiveness of different CRC screening strategies.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>20 000 eligible participants aged 50–74 years are enrolled in five provinces in China. After providing signed informed consent, the participants will be randomised into one of the three screening groups: (1) one-time colonoscopy (n=4000), (2) annual faecal immunochemical test (FIT) (n=8000) and (3) annual risk-adapted screening strategy (n=8000). The risk-adapted screening strategy will use an established CRC risk scoring system, the Asia-Pacific Colorectal Screening score. Participants at high risk of CRC will be referred for colonoscopy, while participants at low risk will be referred for an FIT. Information on clinical reports, epidemiological risk factors and health economic factors will be collected and stored in a web-based data management system. We will further request the participants to donate blood, faecal and saliva samples before conducting the colonoscopy. The primary outcome will be the detection rate of advanced colorectal neoplasia and the secondary outcomes will include the rates of CRC-related mortality, incidence of CRC, participation and complications. The study will last for at least 4 years and the cohort will be followed for 10 years to adequately answer the scientific questions.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>This study was approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences and Peking Union Medical College (18-013/1615). The results of the study will be submitted for publication in peer-reviewed journals and will be discussed by policy and decision makers.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p>ChiCTR1800015506.</jats:p></jats:sec>
doi_str_mv 10.1136/bmjopen-2018-025935
facet_avail Online, Free
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEzNi9ibWpvcGVuLTIwMTgtMDI1OTM1
imprint BMJ, 2019
imprint_str_mv BMJ, 2019
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 2044-6055
issn_str_mv 2044-6055
language English
last_indexed 2024-03-01T15:13:42.48Z
match_str chen2019comparativeevaluationofnovelscreeningstrategiesforcolorectalcancerscreeninginchinatargetcastudyprotocolforamulticentrerandomisedcontrolledtrial
mega_collection BMJ (CrossRef)
physical e025935
publishDate 2019
publishDateSort 2019
publisher BMJ
record_format ai
recordtype ai
series BMJ Open
source_id 49
spelling Chen, Hongda Li, Ni Shi, Jufang Ren, Jiansong Liu, Chengcheng Zhang, Yueming Jiang, Zheng Zhang, Zhihui Dai, Min 2044-6055 2044-6055 BMJ General Medicine http://dx.doi.org/10.1136/bmjopen-2018-025935 <jats:sec><jats:title>Introduction</jats:title><jats:p>Screening for colorectal cancer (CRC) is effective in reducing the disease burden. However, high-level evidence from randomised controlled trials on the effectiveness of CRC screening modalities is still lacking. We will conduct a large-scale multicentre randomised controlled trial in China to evaluate the effectiveness and cost-effectiveness of different CRC screening strategies.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>20 000 eligible participants aged 50–74 years are enrolled in five provinces in China. After providing signed informed consent, the participants will be randomised into one of the three screening groups: (1) one-time colonoscopy (n=4000), (2) annual faecal immunochemical test (FIT) (n=8000) and (3) annual risk-adapted screening strategy (n=8000). The risk-adapted screening strategy will use an established CRC risk scoring system, the Asia-Pacific Colorectal Screening score. Participants at high risk of CRC will be referred for colonoscopy, while participants at low risk will be referred for an FIT. Information on clinical reports, epidemiological risk factors and health economic factors will be collected and stored in a web-based data management system. We will further request the participants to donate blood, faecal and saliva samples before conducting the colonoscopy. The primary outcome will be the detection rate of advanced colorectal neoplasia and the secondary outcomes will include the rates of CRC-related mortality, incidence of CRC, participation and complications. The study will last for at least 4 years and the cohort will be followed for 10 years to adequately answer the scientific questions.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>This study was approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences and Peking Union Medical College (18-013/1615). The results of the study will be submitted for publication in peer-reviewed journals and will be discussed by policy and decision makers.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p>ChiCTR1800015506.</jats:p></jats:sec> Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial BMJ Open
spellingShingle Chen, Hongda, Li, Ni, Shi, Jufang, Ren, Jiansong, Liu, Chengcheng, Zhang, Yueming, Jiang, Zheng, Zhang, Zhihui, Dai, Min, BMJ Open, Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial, General Medicine
title Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_full Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_fullStr Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_full_unstemmed Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_short Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
title_sort comparative evaluation of novel screening strategies for colorectal cancer screening in china (target-c): a study protocol for a multicentre randomised controlled trial
title_unstemmed Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial
topic General Medicine
url http://dx.doi.org/10.1136/bmjopen-2018-025935